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Summary
 
A receptor–ligand interaction exclusive to natural killer (NK) cell–mediated recognition and
triggering of tumor cell destruction has not yet been identified. In contrast, molecules that are
involved in cellular adhesion and regulation of NK cytolysis have been well studied. In this re-
port, a novel tumor surface protein is identified that exhibits characteristics of a recognition
structure for naive NK cells. A tagged ligand–cell adsorption technique revealed a 38.5-kD
plasma membrane protein (p38.5) from a prototypical NK-susceptible cell line (K562) that pre-
ferentially bound to NK cells (CD3
 
2
 
CD5
 
2
 
CD16
 
1
 
) relative to T lymphocytes (CD3
 
1
 
CD5
 
1
 
CD16
 
2
 
). The molecule was purified to apparent homogeneity for further characterization. An
amino acid sequence of an 11-mer internal peptide of p38.5 did not exhibit homology to
known proteins. Affinity-purified antibody generated against this peptide (anti-p38.5) reacted
with a single protein of 38.5 kD on Western blots of whole cell extracts of K562. Flow cytom-
etry and immunoprecipitation studies of surface-labeled tumor cells demonstrated expression of
p38.5 on NK-susceptible tumor cell lines (K562, MOLT-4, Jurkat), whereas p38.5 was not de-
tected on NK-resistant tumor cell lines (A549, Raji, MDA-MB-231). Significantly, p38.5 loss
variants derived from wild-type Jurkat and Molt-4 cell lines exhibited decreased susceptibility
to NK cell–mediated lysis demonstrating a strong association between cell surface expression of
p38.5 and cytotoxicity. Purified p38.5 retained preferential binding to NK cells and inhibited
NK activity in a dose-dependent manner, thereby providing direct evidence of a role in the
lytic process. Binding studies identified a 70-kD membrane protein from NK cells as a possible
receptor for the p38.5 tumor ligand. Consistent with cellular adsorption studies, the 70-kD,
p38.5 binding protein was not detected on T lymphocytes. Based on studies demonstrating se-
lective binding of p38.5 to NK cells, lack of expression on NK-resistant tumor cell lines and
ability of the purified molecule to block cytolysis, we conclude that p38.5 may serve as a rec-
ognition/triggering ligand for naive human NK cells.
 
N
 
aive NK cells (CD3
 
2
 
, CD16
 
1
 
, TCR
 
2
 
), unlike CTL
(CD3
 
1
 
, CD16
 
2
 
, TCR
 
1
 
) provide cell-mediated lytic
activity against virus-infected cells and certain tumors with-
out requirement for activation (1–3). Such unactivated lym-
phocytes, also referred to as resting or naive NK cells, are
capable of destroying a relatively limited spectrum of tumor
cells (1, 4). Upon activation with lymphokines such as IL-2,
NK cells acquire broad anti-tumor lytic activity (lymphokine-
activated killer cells, i.e., LAK cells). The mechanism(s) by
which naive NK cells recognize their target cells is not
completely understood. Interaction of cellular adhesion
molecules and recognition of specific target structure(s) have
been proposed as critical initial events in the cell-mediated
lytic process (1, 5). For example, it is well known that the
initiation of target cell lysis by CTL is due to interaction of
the MHC class I molecules (plus bound peptide) with the
TCR (6, 7). Analogous molecular structures that initiate
the lytic process between NK cells and tumor cells have not
been defined. Although MHC molecules may serve a regu-
latory function for NK cells (8–11), it is clear that their
presence on the surface of tumor cells is not required for
cytolysis, because NK-susceptible cell lines do not express
MHC gene products (11, 12).
A possible feature of NK cell tumor–specific recognition
structures is that the molecules may be exclusively ex-
pressed on NK cells and their susceptible target cells, re-
spectively. We examined this possibility by using a tagged
ligand–cell adsorption technique (13) to reveal surface mol-
ecules of human tumor cells that preferentially bind to NK
cells. Results from these studies identified a 38.5-kD tumor
membrane protein (p38.5) that bound to NK cells and not
at all to T lymphocytes. Functional studies suggest that this
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interaction is necessary for naive NK cell–mediated cyto-
toxicity.
 
Materials and Methods
 
Chemicals, Antibodies, and Cell Lines.
 
N-hydroxy succinamide
ester of biotin (biotin–NHS) was purchased from Calbiochem–
Novabiochem Corp. (La Jolla, CA). Streptavidin alkaline phospha-
tase and all cell culture media and reagents were from GIBCO BRL
(Gaithersburg, MD). Electrophoresis reagents and chemicals were
purchased from Bio-Rad Laboratories (Melville, NY). All other
chemicals used were from Sigma Chemical Co. (St. Louis, MO).
Mouse anti–rabbit IgG was purchased from Pierce (Rockford,
IL), goat anti–rabbit alkaline phosphatase was obtained from
Sigma Chemical Co. (St. Louis, MO). Goat anti–rabbit IgG con-
jugated to FITC was obtained from Tago, Inc. (Burlingame, CA).
Antibody recognizing p38.5 was raised in a rabbit against an 11-
mer synthetic peptide derived from the amino acid sequence of
an internal peptide of the molecule (see below). The synthetic
peptide (250 
 
m
 
g) was mixed with Titermax (CytRx Co. Atlanta,
GA) (1:1 vol/vol) and injected subcutaneously into a rabbit at four
sites as instructed by the manufacturer. Subcutaneous booster in-
jections (100 
 
m
 
g peptide in IFA) were given to the rabbit at bi-
monthly intervals. Serum was collected 1 wk after the third
booster injection. Anti-p38.5 antibodies were affinity purified
from sera using BSA, 11-mer peptide conjugate linked to CNBr–
Sepharose 4B. Affinity-purified antibody had a titer of 1:2,000
and reacted with a single protein of 38.5 kD on Western blots
(see results). Cell lines used in this study were obtained from the
American Type Culture Collection (Rockville, MD) and were
maintained in media according to instructions provided.
 
Lymphocytes.
 
Human peripheral blood lymphocytes (HPBL)
 
1
 
were isolated as described previously (13). In brief, blood ob-
tained from healthy volunteers was diluted 1:1 with HBSS, lay-
ered on Ficoll–Hypaque (Pharmacia, Piscataway, NJ) and centri-
fuged at 200 
 
g
 
 for 20 min. The mononuclear leukocyte fraction
(Ficoll–Hypaque interface) was passed through nylon wool col-
umns to obtain HPBL depleted of B cells and monocytes.
 
Isolation of Naive NK Cells and T Lymphocytes.
 
Naive human
NK cells are defined as freshly isolated CD3
 
2
 
, CD5
 
2
 
, CD16
 
1
 
that exhibit limited target cell specificity, i.e., lytic activity against
K562, but not A549 tumor cells. Activated NK cells, i.e., those
that are stimulated with lymphokines such as I
 
l
 
-2 (LAK), are able
to lyse NK-resistant tumor cells such as A549 (1, 4). Only those
preparations of HPBL that lacked LAK cell activity were used
for the isolation of naive NK cells and T lymphocytes. Isolation
of naive NK cells and T lymphocytes was performed as follows.
Freshly isolated HPBL were suspended in PBS containing 2% fe-
tal bovine serum (FBS) at 20 
 
3
 
 10
 
6
 
 cells/ml and incubated (4
 
8
 
C for
30 min) with anti-CD5, 20 
 
m
 
l/1 
 
3
 
 10
 
6
 
 cells (Becton-Dickinson,
San Jose, CA). Anti-CD5 reactive lymphocytes were captured by
incubating the mixture with sheep anti–mouse IgG-coated mag-
netic beads, 30 
 
m
 
l/1 
 
3
 
 10
 
6
 
 cells (Dynal Inc., Lake Success, NY).
The magnetic beads containing adherent CD5
 
1
 
 cells were washed,
suspended in RPMI supplemented with 15% FBS, and incubated
overnight at 37
 
8
 
C in 5% CO
 
2
 
. Subsequently, CD5-enriched lym-
phocytes (T lymphocytes) were separated from the magnetic
beads by vortexing 2 min and placing the mixture in a magnetic
field. The supernatant containing CD5
 
2
 
 HPBL was incubated
with anti-CD3, 20 
 
m
 
l/10
 
6
 
 cells (Becton-Dickinson, San Jose, CA)
at 4
 
8
 
C for 30 min. Anti-CD3–reactive lymphocytes were sepa-
rated using magnetic beads as described above. The supernatant
was centrifuged to obtain cells that were depleted of CD3
 
1
 
 and
CD5
 
1
 
 lymphocytes (i.e., CD 16
 
1
 
 enriched naive NK cells). The
average phenotype of the T lymphocyte enriched fraction was
 
,
 
3% CD16
 
1
 
, 50% CD4
 
1
 
, and 93% CD3
 
1
 
. These cells did not
exhibit NK or LAK cytolytic activity. The average phenotype of
the negatively selected naive NK cell enriched fraction was 85%
CD 16
 
1
 
, 
 
,
 
3% CD3
 
1
 
. These cells exhibited increased NK cell
lytic activity (60% cytotoxicity at an effector to target E/T ratios
of 100:1) compared with unfractionated HPBL (32% cytotoxicity).
 
Binding of Tumor Plasma Membrane Proteins to Lymphocytes.
 
Plasma membrane proteins of viable tumor cells were labeled
with biotin as described previously (13). In brief, cells ( 
 
.
 
99% vi-
able by trypan blue dye exclusion) were washed three times with
a solution containing 10 mM Hepes, 145 mM NaCl, 4 mM KCl,
11 mM glucose, pH 8.0 (buffer A) and then incubated in the
same buffer with biotin–NHS (1 mM biotin–NHS, 10 
 
3
 
 10
 
6
 
cells/ml) for 1 h at 4
 
8
 
C. Cells were then washed three times with
20 vol of buffer A to remove unreacted biotin. The biotinylated
cells were suspended in 250 mM sucrose with 10 mM Hepes (pH
8.0) and disrupted by N
 
2
 
 cavitation (1,000 psi) in a Parr’s cham-
ber. The resulting suspension was centrifuged at 200 
 
g
 
 for 5 min
to remove undisrupted cells and the supernatant was centrifuged
at 30,000 
 
g
 
 for 20 min to obtain a crude membrane fraction.
Membranes were washed once with 10 mM sodium borate, 10
mM benzamidine, 1 mM EDTA, 1 mM iodoacetamide, 1 mM
PMSF, pH 8.0 (buffer B), and incubated in the same solution
with 1% Triton X-100 at 4
 
8
 
C overnight. Solubilized membrane
proteins were obtained as the 30,000 
 
g
 
 supernatant of the deter-
gent treated membranes and dialyzed extensively against buffer B
containing 0.05% Triton X-100, as described previously (13).
Biotin-labeled solubilized tumor plasma membrane proteins
were reacted with freshly isolated naive NK cells and T lympho-
cytes at a ratio of 2:1 (on the basis of cell numbers) in RPMI-
1640 supplemented with 15% FBS at 4
 
8
 
C for 2 h. The reacted
cells were washed twice with media and three times with buffer
A. Finally, cells were solubilized in Laemmli sample buffer and
the solubilized proteins were subjected to SDS-PAGE and West-
ern blotting. Biotinylated tumor membrane proteins that bound
to lymphocytes were identified with a streptavidin biotin detec-
tion system as described previously (13).
 
Purification of Tumor Membrane Proteins.
 
Membrane proteins were
purified as described previously (13). Approximately 10
 
11
 
 cells of
erythroleukemia cell line (K562) were washed three times with
PBS and used to prepare plasma membrane proteins as described
above. Solubilized membrane proteins were extensively dialyzed
against buffer B and subjected to preparative SDS-PAGE. A ver-
tical portion of the gel was sliced and stained with Coomassie
blue to locate desired proteins. Protein bands of interest were cut
from the gel, eluted, and further purified by SDS-PAGE. A por-
tion of the purified protein was extensively dialyzed against 10 mM
Tris–HCl, pH 8.0 and used for cytotoxicity inhibition studies or
dialyzed against buffer B and labeled with biotin as described above
for study of its binding properties to various lymphocyte subsets.
A portion of the purified protein was also isolated on nitrocellu-
lose paper after SDS-PAGE using the method described by Ae-
bersold et al. (14) for the purpose of internal amino acid sequence
analysis of the protein subsequent to in situ protease digestion (Har-
vard Microchemistry Laboratory, Cambridge, MA).
 
Immunoprecipitation of Surface-labeled Proteins.
 
Immunoprecipi-
tation of plasma membrane proteins was performed by initially
 
1
 
Abbreviations used in this paper:
 
 FBS, fetal bovine serum; HPBL, human
peripheral blood lymphocytes; Hsp, heat shock protein. 
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incubating anti-p38.5 with anti–rabbit IgG coupled to CNBr–
Sepharose 4B at 4
 
8
 
C for 90 min in PBS containing 1% BSA (13).
The reacted beads were then washed three times with buffer and
incubated at 4
 
8
 
C for 90 min with surface-biotinylated tumor
plasma membrane proteins. Beads were then washed three times
with PBS containing 1% BSA and two times with PBS alone, sus-
pended in Laemmli SDS-PAGE sample buffer, and boiled for 10
min. The supernatant was subjected to SDS-PAGE and proteins
transblotted to Immobilon-P membrane (Millipore Corp., Bed-
ford, MA). Anti-p38.5 immunoprecipitated biotinylated tumor
membrane proteins were identified on Western blots by reaction
with streptavidin–biotin detection system.
 
Fluorescence-activated Flow Cytometry.
 
Approximately, 10
 
6
 
 cells
were washed three times with PBS containing 0.1% BSA (PBS–
BSA) and incubated with appropriately diluted anti-p38.5 at 4
 
8
 
C
for 30 min. Cells were then washed three times with PBS–BSA
and reacted with FITC–F(ab
 
9
 
)
 
2
 
 goat anti–rabbit IgG for 30 min at
4
 
8
 
C. Finally, cells were washed three times with PBS–BSA, re-
suspended to a concentration of 10
 
6
 
/ml, and analyzed on a FAC-
Sort
 
Ò
 
 Flow Cytometer (Becton-Dickinson, San Jose , CA).
 
Lymphocyte-mediated Cytotoxicity.
 
Cytolysis of tumor cells by
lymphocytes was measured as described previously (13, 15). In
brief, 100 
 
m
 
l of 
 
51
 
Cr-labeled target cells (2 
 
3
 
 10
 
4
 
 cells/ml) was
mixed with 100 
 
m
 
l of lymphocytes (2 
 
3
 
 10
 
6
 
 cells/ml) to yield se-
rial twofold dilutions of E/T cell ratios of 100:1 to 6:1. Cells were
incubated at 37
 
8
 
C for 3 h in 5% CO
 
2
 
. Incubation of target cells
without the effector cells and in media alone served as control for
spontaneous release of 
 
51
 
Cr, and wells without effector cells but
with 1% SDS provided the maximum amount of radioactivity
present. Cytolysis was calculated as percent cytotoxicity 
 
5
 
 100 
 
3
 
([CPM
 
exp
 
 
 
2
 
 CPM
 
spont.
 
] / [CPM
 
max
 
 
 
2
 
 CPM
 
spont.
 
]).
 
Results
 
Binding of Tumor Plasma Membrane Protein p38.5 to Hu-
man Lymphocytes.
 
A tagged ligand–cell adsorption tech-
nique (13) was used to identify membrane proteins from a
susceptible tumor cell line that preferentially bind to NK
cells. Solubilized membrane proteins from surface biotin-
labeled K562 cells were reacted with immunomagnetic bead–
enriched freshly isolated naive NK cells or T lymphocytes.
Approximately 14 common bands were detected on West-
ern blots of K562 plasma membrane proteins that bound to
both NK cells and T lymphocytes (Fig. 1). However, a sin-
gle band of 38.5 kD (p38.5) was detected from NK cell ad-
sorbed preparations, but was not observed in T lymphocyte
adsorbed preparations. This initial result suggested the pos-
sibility that p38.5 interacted with a receptor on the surface
of naive NK cells that was not expressed on T lympho-
cytes. Accordingly, p38.5 was purified by preparative SDS-
PAGE to apparent homogeneity for additional studies. The
purified protein resolved as a single band of 38.5 kD mo-
lecular mass upon SDS-PAGE (Fig 2, lane 
 
A
 
). p38.5 was
labeled with biotin for use in studying its binding property
to lymphocyte subsets (in a similar manner as that described
for proteins from the crude membrane preparation). Biotin-
ylated p38.5 bound extensively to the NK cell–enriched
fraction (Fig. 2, lane 
 
D
 
) and not at all to the enriched T lym-
phocytes (Fig. 2, lane 
 
C
 
). In this experiment, unfraction-
ated cells bound a slight amount of p38.5 (Fig. 2, lane 
 
B
 
),
which is consistent with the low percentage of NK cells in
peripheral blood lymphocyte specimens. These data dem-
onstrate that SDS-PAGE–purified p38.5 retained its prefer-
ential binding property for naive NK cells.
 
Structural Characteristics of p38.5.
 
Initial attempts to ob-
tain a partial amino acid sequence of the purified p38.5
were unsuccessful because the NH
 
2
 
 terminus of the mole-
cule was blocked. Consequently, p38.5 was transferred onto
nitrocellulose paper and subjected to in situ protease diges-
tion (14). Amino acid sequence analysis of resultant pep-
tides was performed at the Harvard Microchemistry Labo-
ratory (Cambridge, MA). An 11-mer amino acid sequence
of an internal peptide was obtained with a high degree of
confidence (Table 1). Comparison of this sequence with
known sequences of proteins in Gen Bank did not reveal
significant homology. Treatment of p38.5 with sulfhydryl
reducing agents (2-mercaptoethanol and dithiothreitol) or
deglycosylating enzymes (
 
O
 
-glycosidase, 
 
N
 
-acetylneuramin-
Figure 1. Binding of K562
membrane proteins to subsets of
HPBL. Membrane proteins from
surface biotinylated K562 cells
were reacted with freshly iso-
lated viable CD32, CD161 en-
riched naive NK cells and CD31
CD162-enriched T lympho-
cytes. Reacted lymphocytes
were washed, solubilized in
Laemmli sample buffer, and pro-
teins resolved by SDS-PAGE.
Lymphocyte-bound biotiny-
lated tumor plasma membrane
proteins were detected on West-
ern blots with streptavidin–alka-
line phosphatase. Lane A, a rep-
resentative blot of surface-labeled
K562 membrane proteins that
bound to enriched T lymphocytes. Lane B, a representative blot of sur-
face-labeled K562 membrane proteins that bound to enriched NK cells.
Densitometry analysis employing Gelbase software (UVP System 5000;
Upland, CA) identified 14 common bands in lanes A and B of the origi-
nal blot. A protein peak of 38.5 kD was present only in the NK cell ad-
sorbed sample.
Figure 2. Binding of purified
p38.5 to HPBL. The binding re-
action with purified p38.5 and
detection of bound biotin-labeled
p38.5 was performed as described
for experiments in Fig. 1. Lane
A, a Western blot of Coomassie
blue–stained purified p38.5 K562
membrane protein. Lane B, a
Western blot of an extract of via-
ble HPBL that were reacted with
purified biotin-labeled p38.5
showing slight reactivity. Lane
C, a Western blot of an extract
of viable enriched T lympho-
cytes that were reacted with pu-
rified biotin-labeled p38.5 revealing little or no reactivity. Lane D, a West-
ern blot of an extract of viable enriched NK cells that were reacted with
purified biotin-labeled p38.5 demonstrating extensive reactivity. 
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idase II and peptide-N-glycosidase F, deglycosylation kit;
Glyko, Inc., Novato, CA) did not alter the molecular mass
of the molecule, suggesting that the isolated protein is a
monomer and nonglycosylated (Das, B., unpublished data).
Expression of p38.5 on Established Tumor Cell Lines. Because
p38.5 (derived from K562 cells) exhibited selective binding
to naive NK cells, it was of interest to examine the expression
of this molecule on the plasma membrane of NK-resistant
cell lines as well as other NK-sensitive tumor cell lines. Af-
finity-purified antibody raised against the internal 11-mer
synthetic peptide of p38.5 (anti-p38.5) was used for this
purpose. Anti-p38.5 was reacted with three NK-sensitive and
three NK-resistant tumor cell lines and analyzed separately
by flow cytometry. As shown in Fig. 3 A, anti-p38.5 reacted
with the surface of NK-sensitive tumor cell lines, K562
(erythroleukemia), Jurkat (T cell lymphoma), and Molt-4 (T
cell leukemia). In contrast, anti-p38.5 did not bind to the
three NK-resistant tumor cell lines A549 (lung adenocarci-
noma), Raji (Burkitt lymphoma), and MDA–MB231 (breast
carcinoma). Plasma membrane expression of p38.5 was also
studied by anti-p38.5 immunoprecipitation of surface-labeled
(biotin) membrane proteins of the above tumor cells. West-
ern blot analysis of the immunoprecipitates showed the pres-
ence of a single 38.5-kD biotinylated protein from NK-sen-
sitive cell lines, whereas biotinylated proteins were not
observed when the NK-resistant cell lines were employed
(Fig. 3 B). These results demonstrate an association between
the expression of p38.5 on the surface of tumor cell lines
and their susceptibility to NK cell–mediated lysis.
Cell Surface Expression of p38.5 on NK-resistant Variants of
Jurkat and Molt-4 Cell Lines. Though the expression of
p38.5 is associated with susceptibility of well-established
tumor cell lines to NK cell–mediated cytolysis, one must
interpret such data with caution as the cell lines are derived
from different tissues and are likely to have been trans-
formed by different mechanisms. This issue could however
be more readily addressed by examining the association of
NK susceptibility and p38.5 expression in variants derived
from wild-type tumor cells. After long-term culture of Jur-
kat and Molt-4 cell lines, we observed a substantial reduc-
tion in their susceptibility to NK cell–mediated cytotoxic-
ity. These variant cell lines were then analyzed for surface
expression of p38.5 by anti-p38.5 immunoprecipitation. As
shown in Fig. 4, variant cell lines exhibited decreased sus-
ceptibility to lysis by NK cells and expressed significantly
lower amounts of p38.5 on their surfaces as compared with
the wild-type parental cell lines.
Effect of Purified p38.5 on NK Cell–mediated Cytolysis.
The preferential binding of p38.5 to NK cells suggested
that the molecule may be involved as a ligand in the cy-
tolytic process mediated by naive NK cells. To examine
this possibility directly, a purified preparation of p38.5 was
incubated with human lymphocytes and then tested in a
standard cytotoxicity assay against 51Cr-labeled K562 target
Figure 3. Plasma membrane expression of p38.5 on NK-susceptible
and NK-resistant tumor cell lines. (A) Flow cytometry analysis of anti-
p38.5–treated tumor cell lines. Cells were treated with anti-p38.5 fol-
lowed by goat anti–rabbit F(ab9)2 IgG–FITC (—). Control tumor cells
were treated with secondary antibody alone (- - -). Nonimmune rabbit
serum had similar reactivity as secondary antibody alone (data not shown).
The NK-sensitive cell lines, K562, Jurkat, and Molt-4, were positive for
anti-p38.5, whereas NK-resistant cell lines, A549, Raji, and MDA-MB-
231, were not reactive with p38.5 antibody. (B) Analysis of anti-p38.5
immunoprecipitates from surface-labeled cells. Western blots of anti-
p38.5 immunoprecipitated proteins from surface biotinylated cells: K562
(lane A), Jurkat (lane B), Molt-4 (lane C), Raji (lane D), A549 (lane E),
and MDA-MB-231 (lane F). Proteins in these lanes were probed with
streptavidin–alkaline phosphatase to detect cell surface-biotinylated pro-
teins. Biotin labeling and immunoprecipitation of plasma membrane pro-
teins have been described previously (13).
Table 1. Amino Acid Sequence of an Internal Peptide of K562 
Membrane Protein, p38.5
1  5  10
F V N W Q V D G E Y R
p38.5 was purified from an extract of K562 membrane proteins by pre-
parative SDS-PAGE as described in Materials and Methods and the pu-
rified protein was electroblotted onto nitrocellulose paper. In situ pro-
tease treatment of the blotted protein and HPLC chromatography of
the p38.5 digest were performed according to Aebersold et al. (14). A
total of 152 peaks were detected on the chromatogram but only a few
appeared to be ammenable to sequencing (based on the intensity and
the homogeneity of the peaks). Peaks 17, 42, 72, and 102 were se-
quenced, but only peak 72, as shown above, provided unambiguous
amino acid data.1739 Das et al.
cells. Incubation of lymphocytes with the purified p38.5
preparation inhibited naive NK activity in a concentration-
dependent manner (Fig. 5). A K562 membrane protein of
40 kD, purified by the same procedure as p38.5, did not af-
fect NK activity. These data provide direct evidence that
interaction of tumor surface protein p38.5 with its NK cell
receptor is necessary for cytotoxicity, because binding of
soluble ligand to the NK cells before contact with K562
cells inhibited their lysis.
Characterization of NK Cell Receptor of p38.5. To delin-
eate further the preferential interaction of p38.5 with NK
cells relative to T lymphocytes, we conducted investiga-
tions to identify an interactive molecular species on effector
cells. In direct binding assays, biotin-labeled purified p38.5
was reacted with either NK cell or T lymphocyte mem-
brane proteins that had been previously immobilized on
Western blots. Labeled p38.5 was detected as a single band
at 70 kD on blots of NK cell membrane proteins, whereas
reactive bands were not detected on blots of T lymphocyte
membrane proteins (Fig. 6). This result suggests that a pro-
tein of 70 kD from naive NK cells binds cell surface p38.5
from NK cell–susceptible tumors and that the 70-kD pro-
tein is either not present or is present in substantially lower
amounts in T lymphocytes.
To establish the immunologic identity of the ligand bound
to the NK cell receptor, anti-p38.5 serum was used. A West-
ern blot of peripheral blood lymphocyte membrane pro-
teins was initially incubated with a solubilized crude extract
of K562 membrane proteins, washed, and then reacted
with anti-p38.5. The antiserum reacted with a band at 70
kD rather than at 38.5 kD (Fig. 7, compare lanes C and D
to lane A). Western blots of lymphocyte membrane pro-
teins that were not preincubated with the tumor proteins
did not react with anti-p38.5 (Fig. 7, lane B). These results
suggest that the 38.5-kD surface molecule from K562 cells
that binds to the 70-kD naive NK cell protein contains the
11-mer peptide to which antibody was raised. We con-
clude that the 11-mer epitope of p38.5 is probably not di-
rectly involved in the receptor–ligand interaction. (Presum-
ably, if the p38.5–70-kD interaction included the 11-mer
Figure 5. Effect of purified K562 membrane proteins on naive NK
cell–mediated cytotoxicity. HPBL were preincubated with the indicated
amount of purified proteins (z45 ng/ml based on amino acid sequence
data) at 378C for 30 min and then added to 51Cr-labeled K562 cells at an
E/T ratio of 100:1 as previously described. Percent cytotoxicity was de-
termined after 3 h incubation by the release of 51Cr (13, 15). Representa-
tive data of two experiments is shown. The cytotoxicity data were ana-
lyzed by the Student’s t test. p38.5, 10 ml, not significant; p38.5, 25 ml, P
,0.01; p38.5, 50 ml, P ,0.001 compared with buffer control. p40 values
compared with buffer control were not significant at any concentration.
Figure 6. Identification of a p38.5-
binding naive NK cell membrane pro-
tein by direct interaction on Western
blots. Lane A, a Western blot of Coo-
massie blue–stained purified p38.5 K562
membrane protein. Lane B, a Western
blot of T lymphocyte proteins that were
reacted with purified biotinylated p38.5.
Bound p38.5 was not detected on this
blot indicating the absence of reactive T
lymphocyte proteins. Lane C, a Western
blot of NK cell proteins that were re-
acted with purified biotinylated p38.5.
Labeled p38.5 was detected at z70 kD
demonstrating a preferential interaction with the latter immobilized NK
cell protein. The reactivity of p38.5 with the 70-kD NK cell protein was
markedly reduced when an extensively denatured (by boiling) prepara-
tion of NK cell proteins was used (data not shown).
Figure 4. Relationship between cell surface expression of p38.5 on
normal and variant tumor cell lines and susceptibility of tumors to NK
cell–mediated lysis. Parental cell lines, Mp, Jp; variant cell lines, Mv, Jv.
After long term culture of Jurkat (J) and Molt-4 (M) cell lines, substantial
reduction in NK cell–mediated cytolysis was observed. These variant cell
lines were analyzed for surface expression of p38.5 by specific antibody as
described above. Membrane proteins derived from 1 3 106 cells were
loaded in each lane. The level of cytolytic activity was directly related to
the apparent degree of expression of surface p38.5. Gelbase analysis (UVP,
Upland, CA) of the blots for protein bands from parental cell lines dem-
onstrated relative single peak heights of 28 and 25, respectively. Similar
analysis of the blots for protein bands from the variant cell lines did not
reveal anti-p38.5 reactive protein. However, a very light band was visible
by the naked eye (for Mv).1740 p38.5: A Novel NK Cell Target Molecule
epitope of p38.5, antibody to the latter determinant could
not bind to the complex).
The following experiment was performed to confirm
that a 70-kD NK cell protein that specifically binds p38.5 is
localized on the plasma membrane. Solubilized membrane
proteins from surface-biotinylated naive NK cells were ap-
plied to a p38.5-Sepharose 4B column. After extensive wash-
ing with high salt buffer, specifically bound protein was ex-
tracted in denaturing buffer and subjected to SDS-PAGE
and Western blot analysis. A single discreet biotinylated band
of 70 kD from NK cells was detected on the blots suggest-
ing that this p38.5 binding protein is located on the exte-
rior of the plasma membrane (Fig. 8, lane B). One possibil-
ity is that the 70-kD, p38.5 binding protein is the inducible
form of heat shock protein (Hsp 70). We performed flow
cytometry studies using antibody to Hsp 70 (Stressgen Bio-
tech. Corp., Victoria, BC Canada; Clone C92F3A-5) to de-
termine surface expression of this moleule on T and NK
cells. Such experiments indicated that neither NK nor T cells
expressed Hsp70 on their plasma membranes in contrast with
K562 cells that served as a positive control (Norin, A.J., un-
published data).
Discussion
Previous attempts during the past two decades to identify
recognition structures exclusive to NK cell–tumor interac-
tion have been unsuccessful (reviewed in reference 8), though
important components on both NK cells and on tumor
cells that contribute to cellular adhesion and regulation of
the cytolytic process have been revealed (5, 8–12). How-
ever, these receptor–ligand interactions do not appear to be
unique to NK cells, because they also occur between T lym-
phocytes and respective target cells (10). The limited num-
ber of NK cells available for biochemical studies (,5% in
peripheral blood) has undoubtedly contributed to the diffi-
culty in analysis of NK cell–specific receptor–ligand inter-
actions. Many investigators have addressed this issue by the
expansion of freshly isolated NK cells in vitro using a vari-
ety of culture systems employing growth factors and/or
feeder cells (11, 12, 16). Such techniques have provided
sufficient numbers of cells for immunologic and biochemi-
cal studies but at the expense of altering the phenotype of
the freshly isolated NK cells from a naive state to an acti-
vated one, as demonstrated by induction of the Lag 3 pro-
tein (17). It is possible that activation results in decreased ex-
pression of naive NK cell recognition structure(s), thereby
preventing their detection. In the present study, several
strategies were used to overcome the difficulties of hetero-
geneity and the low frequency of NK cell in HPBL prepa-
rations. Only freshly isolated NK cells were used. Cells from
individuals that demonstrated activity against NK-resistant
LAK-sensitive tumor cell lines were not used, because the
activated NK cells in these fresh preparations might mask the
detection of naive NK cell–specific ligands. Finally, a tagged
ligand–cell adsorption technique (13) was used with enriched
NK cell preparations to enhance the likelihood of detection of
tumor proteins that selectively bound to the naive killer cells.
Using the above approaches and additional biochemical
and immunologic techniques, we demonstrate a novel 38.5-
kD protein on the plasma membrane of certain tumor cell
lines that preferentially reacts with a surface component of
naive human NK cells. The interaction appears to be unique
to NK cells, because T lymphocytes did not bind p38.5.
However, binding studies have not been conducted with B
cells, monocytes, or polymorphonuclear leukocytes. In fur-
ther experiments, a 70-kD protein on the plasma mem-
brane of NK cells was identified as a p38.5 binding mole-
cule. Consistent with p38.5 cellular binding studies, a 70-kD
receptor was not detected on T lymphocytes. Addition of
purified p38.5 to fresh lymphocyte preparations before in-
cubation with K562 target cells substantially decreased NK
cell lytic activity. Preferential interaction of p38.5 with NK
cells and its blocking activity in functional assays are prop-
erties consistent with a role in an early recognition event in
NK cell–mediated tumor cytolysis.
Additional evidence of a role for p38.5 as a target ligand
in naive NK cell–mediated cytotoxicity is provided by data
Figure 7. Immunologic iden-
tification of the p38.5 ligand
bound to the 70 kD NK cell
protein. All lanes were devel-
oped with goat anti–rabbit alka-
line phosphatase. Lane A, a
Western blot of K562 membrane
protein extract that was reacted
with affinity-purified anti-
p38.5. Lane B, a Western blot of
HPBL membrane proteins re-
acted with affinity-purified anti-
p38.5. Note the absence of anti-
p38.5–reactive proteins. Lane C, a
Western blot of HPBL membrane proteins reacted with K562 membrane
extracts for 2 h at ambient temperature, washed, and probed with anti-
p38.5. Note the detection of a band at an approximate molecular mass of
70 kD. Lane D, same as lane C with twice the amount of K562 mem-
brane proteins.
Figure 8. Plasma membrane
localization of the 70-kD NK
cell tumor binding protein. Solu-
bilized membrane proteins from
surface-biotinylated naive NK cells
were applied to a p38.5–Sepharose
4B affinity column. After exten-
sive washing with 0.5 M NaCl
buffer to remove nonspecifically
bound NK cell membrane pro-
teins, remaining proteins were
eluted by solubilization of the
beads with Laemmli sample buffer
and resolved by SDS-PAGE.
p38.5–Sepharose 4B–bound NK
cell membrane proteins were
detected on Western blots using
standard streptavidin–alkaline
phosphatase reaction. Lane A, crude extract of NK cell membrane pro-
teins from surface-biotinylated NK cells before affinity chromatography.
Lane B, a Western blot of NK cell membrane protein(s) specifically
bound to the p38.5 affinity column. A single discreet NK cell band at 70
kD was detected after affinity chromatography.1741 Das et al.
demonstrating an association of the expression of this mol-
ecule and susceptibility to cytolysis of different tumor cell
lines. Flow cytometry and immunoprecipitation studies (of
surface labeled cells) revealed that p38.5 is expressed on NK
susceptible targets such as K562, MOLT-4, and Jurkat,
whereas this molecule was not detected on the plasma mem-
brane of NK-resistant LAK-sensitive targets such as Raji,
A549, and MDA-MB-231, suggesting that p38.5 is not in-
volved in LAK-mediated cytotoxicity. The functional role
of p38.5 in NK cell–mediated cytolysis was also demon-
strated in studies of p38.5 loss variants. After long-term cul-
ture of wild-type, NK-sensitive Jurkat and Molt-4 cell lines,
variants were isolated that exhibited decreased levels of
p38.5 and reduced susceptibility to lysis by NK cells. This
property was not due to a phenotypic alteration in the cells
as a result of culture conditions, because resistant clones were
obtained at limiting dilution (Norin, A.J., unpublished data).
These studies clearly establish a strong association between
the expression of p38.5 on the tumor plasma membrane
and susceptibility to NK cell–mediated cytolysis.
Recent studies suggest that cytolytic activity is affected
by recognition of HLA class I polymorphisms on target cells
by NK cell receptors of the C-lectin family (CD94) (18) or
members of the immunoglobulin multi gene family (p50/
p58) (19–24). These receptors, which we note are detected
on both T cells as well as NK cells, may downregulate or
upregulate cytolytic activity (10, 20, 25) depending on the
subtype of receptor and/or the presence of cytosol associ-
ated clonotypic signaling molecules (18, 21–24). Inhibitory
receptors apparently interfere with proximal signaling events
such as Ca21 flux, phospholipase Cg2 activity, and inhibi-
tion of specific tyrosine kinases activities (lck and ZAP-70),
whereas the activity of other tyrosine kinases may remain
unchanged (18, 26, 27). Experimental results in the current
study are likely not influenced by the above families of
molecules, because K562 cells do not express HLA class I
or class II molecules (11, 12).
Current concepts regarding the mechanism of lymphocyte-
mediated cytolysis have focused on three alternative path-
ways: (a) Fas–FasL-induced apoptosis of tumor cells (28–33),
(b) extracellular ATP-mediated osmotic lysis (13, 34–36),
and (c) granule exocytosis of effector molecules such as per-
forin and granzymes (29, 37–40). Clearly, NK cell–induced
cytolysis is not mediated by Fas–FasL interaction, because
K562 tumor cells do not express Fas and naive NK cells do
not express FasL (41; Das, B., unpublished data). Previous
reports by us and others have suggested that NK cells use
the ATP–osmotic lysis pathway (13, 35) and the granule
exocytosis pathway (28, 33). Further studies are likely to re-
veal which lytic pathway is mediated by the interaction of
tumor surface ligand p38.5 with NK cell plasma membrane
proteins.
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